We question the wisdom of these choices,” referring to the new board members named, J. Daniel Plants, managing partner of Voce, said in a Feb. 27 letter to the ConMed board.
Voce had earlier suggested different board appointees and said the nominees named in the Coppersmith agreement “cast significant doubt, in our view, as to whether this was the result of a genuine assessment of the quality and fitness of the Board’s designees or simply an effort by the Board to depict itself as responsive to shareholder concerns while attempting to insulate itself from the possible election of our nominees.”